The Center for Biosimilars® recaps the top stories for the week of July 15, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 15, 2019.
Number 5: Coherus BioSciences says that, 6 months after launching its biosimilar pegfilgrastim, it has produced more than 400,000 syringes of the product.
Number 4: A rheumatology practice says that using a value-based pathway for rheumatoid arthritis has led to increased biosimilar use.
Number 3: Recent research shows that the Bipartisan Budget Act resulted in a decrease in out-of-pocket spending for biosimilars, but out-of-pocket spending on specialty generics has risen.
Number 2: According to the Congressional Budget Office, enacting the Lower Health Care Costs Act would reduce the deficit by more than 7 billion dollars by 2029.
Number 1: Celltrion announced that it is launching its first clinical trial of biosimilar CT-P39 referencing Xolair. The company plans to commercialize the biosimilar in 2022.
Finally, last week, our e-newsletter asked whether you think that shifting away from buy-and-bill practices for oncology drugs would help reduce costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.